ASCO 2012 Report – New treatment option for women with platinum resistant ovarian cancer
by Marybeth Burke – Adding bevacizumab to chemotherapy halves the risk of the disease getting worse in platinum resistant patients with ovarian cancer,
by Marybeth Burke – Adding bevacizumab to chemotherapy halves the risk of the disease getting worse in platinum resistant patients with ovarian cancer,
by Marybeth Burke – Crizotinib demonstrated significant anti-tumour activity in patients with advanced non-small cell lung cancer (NSCLC) harbouring ROS1 rearrangements,
by Marybeth Burke – Women treated for childhood cancer with chest radiation therapy have a high risk of developing breast cancer at a young age, comparable to that… read more.
by Marybeth Burke – Regorafenib significantly improved progression-free survival (PFS) and disease control rate (DCR) in patients with advanced gastrointestinal stromal tumours (GIST) that progress due to resistance… read more.
by Marybeth Burke – The investigational agent trastuzumab emtansine (T-DM1) demonstrated improved efficacy over capecitibine plus lapatinib and improved progression-free survival (PFS) in women with HER2-positive locally advanced… read more.
by Marybeth Burke – Median progression-free survival (PFS) was significantly greater in the trametinib group, 4.8 months, vs the chemotherapy group, 1.4 months, according to a study presented
by Marybeth Burke – Wisconsin grown ginseng significantly reduced cancer related fatigue in patients receiving cancer treatment after 8 weeks of ginseng treatment,
by Marybeth Burke – Continuous hormonal therapy is more effective than intermittent hormonal therapy for men with hormone-sensitive metastatic prostate cancer with minimal disease spread,
by Marybeth Burke – Some of the most essential mainstays in cancer treatment drugs for adults and children are in short supply, Michael Link, M.D., president of the… read more.
by Marybeth Burke – The investigational drug BMS-936558 caused tumour shrinkage in up to a quarter of patients with advanced melanoma, kidney and NSCLC cancers,
by Marybeth Burke – Afatinib, an irreversible ErbB-family blocker, delays progression of advanced lung cancer in patients with epidermal growth factor receptor (EGFR) mutations compared with standard chemotherapy,
It is estimated that as many as 24 million European men aged 50 and over experience bothersome urinary symptoms.1,2 Yet, despite experiencing symptoms, men typically wait nearly two… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.